{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:59:56Z","timestamp":1778529596935,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T00:00:00Z","timestamp":1561248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["106-N3626"],"award-info":[{"award-number":["106-N3626"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["107-S3816"],"award-info":[{"award-number":["107-S3816"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["107-N4041"],"award-info":[{"award-number":["107-N4041"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology","award":["MOST 105-2314-B-303-008"],"award-info":[{"award-number":["MOST 105-2314-B-303-008"]}]},{"name":"Ministry of Science and Technology","award":["MOST 106-2314-B-002-136"],"award-info":[{"award-number":["MOST 106-2314-B-002-136"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jfma.2019.06.014","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T17:17:17Z","timestamp":1562174237000},"page":"1187-1192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C"],"prefix":"10.1016","volume":"118","author":[{"given":"Shih-Jer","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Chin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jyun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chi","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yuh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.06.014_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","article-title":"Hepatitis C virus infection in Taiwan: past, present, and future","volume":"115","author":"Kao","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2019.06.014_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2019.06.014_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/hep.28387","article-title":"Hepatitis C viral infection increases the risk of lymphoid-neoplasms: a population-based cohort study","volume":"63","author":"Su","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.06.014_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/apt.12391","article-title":"Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan","volume":"38","author":"Hsu","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2019.06.014_bib6","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1038\/srep09954","article-title":"Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma","volume":"5","author":"Hsu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2019.06.014_bib7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.014_bib8","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.014_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","article-title":"Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV","volume":"154","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2019.06.014_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209299","article-title":"Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan","volume":"13","author":"Liu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2019.06.014_bib11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/jgh.13912","article-title":"Real-world effectiveness and safety of paritaprevir\/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan","volume":"33","author":"Liu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2018.09.005","article-title":"Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data","author":"Hong","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jfma.2019.06.014_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2019.06.014_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 Weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.014_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.06.014_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 Weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2019.06.014_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D'Ambrosio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib21","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2019.06.014_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-018-1520-9","article-title":"Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures","volume":"54","author":"Osawa","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2019.06.014_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.13328","article-title":"Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real-world cohort study","author":"Ogawa","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2019.06.014_bib24","author":"AbbVie Inc"},{"key":"10.1016\/j.jfma.2019.06.014_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.06.014_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.06.014_bib27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11894-014-0372-6","article-title":"Utilization of FibroScan in clinical practice","volume":"16","author":"Bonder","year":"2014","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jfma.2019.06.014_bib28","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2019.06.014_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"Beste","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib31","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/hep.29181","article-title":"Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals","volume":"66","author":"Soria","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.06.014_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOG.0000000000000431","article-title":"Direct-acting antiviral treatment for patients with hepatocellular carcinoma","volume":"34","author":"Kushner","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jfma.2019.06.014_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis","author":"Ji","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.06.014_bib34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.29126","article-title":"Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma","volume":"66","author":"Saberi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.06.014_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease","author":"Gane","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2019.06.014_bib36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/apt.15218","article-title":"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study","volume":"49","author":"Atsukawa","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2019.06.014_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection","volume":"67","author":"Toyoda","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.06.014_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis","volume":"53","author":"Chayama","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2019.06.014_bib39","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J Pharm Sci"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619305327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619305327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T18:53:11Z","timestamp":1610218391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664619305327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0929664619305327"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.06.014","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}